Study of VVN001 Ophthalmic Solution in Dry Eye Disease

Phase 2 Completed 169 enrolled VivaVision Biotech, Inc

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2a, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and tolerability and to explore the efficacy activity of VVN001 ophthalmic solution versus vehicle in subjects with dry eye disease.

Timeline

Start: 2020-12-03
Primary completion: 2021-12-01
Completion: 2021-12-01

Outcome

Missed primary endpoint

paper The primary and first secondary outcomes were not met. PMID 36586669 ↗

Publications

Results Tauber J, Evans D, Segal B, Li XY, Shen W, Lu C, Novack GD; VVN001-CS201 Study Group. A phase 2a, double-masked, randomized, vehicle-controlled trial of VVN001 in subjects with dry eye disease. Ocul Surf. 2023 Apr;28:18-24. doi: 10.1016/j.jtos.2022.12.007. Epub 2022 Dec 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VVN001	Small molecule	1 %	—
Subject	VVN001	Small molecule	5 %	—